How This Biotech CEO Takes Smart Risks. Meet Joe Payne CEO ArcturusRx $ARCT

How This Biotech CEO Takes Smart Risks





Name: Joe Payne





Title: President & CEO





Website: ArcturusRx.com





Ticker: $ARCT





Bio:


Joseph E. Payne, is the President and Chief Executive Officer of
Arcturus Therapeutics. He serves on Arcturus’s Board since March
2013. He brings with him an exceptional track record of ushering
novel therapeutics to the clinic including targeted RNA medicines
utilizing lipid-mediated delivery technologies. Joseph’s
background includes over 20 years of successful drug discovery
experience at Merck Research Labs, DuPont Pharmaceuticals,
Bristol-Myers Squibb, Kalypsys, and Nitto as evidenced by over 40
publications and patents, and several investigational new drug
(IND) clinical candidates. His academic training includes a
Bachelor's Degree in Chemistry, magna cum laude from Brigham
Young University, a Master of Science in Synthetic Organic
Chemistry from the University of Calgary and Executive Training
Certification from MIT Sloan School of Management.








About Arcturus:


Founded in 2013 and based in San Diego, California, Arcturus
Therapeutics Holdings Inc. (Nasdaq: ARCT) is a commercial mRNA
medicines and vaccines company with enabling technologies: (i)
LUNAR lipid-mediated delivery, (ii) STARR mRNA Technology
(sa-mRNA) and (iii) mRNA drug substance along with drug product
manufacturing expertise. Arcturus developed KOSTAIVE, the first
self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the
world to be approved. Arcturus has an ongoing global
collaboration for innovative mRNA vaccines with CSL Seqirus, and
a joint venture in Japan, ARCALIS, focused on the manufacture of
mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA
therapeutic candidates to potentially treat ornithine
transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along
with its partnered mRNA vaccine programs for SARS-CoV-2
(COVID-19) and influenza. Arcturus’ versatile RNA therapeutics
platforms can be applied toward multiple types of nucleic acid
medicines including messenger RNA, small interfering RNA,
circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene
editing therapeutics. Arcturus' technologies are covered by its
extensive patent portfolio (over 400 patents and patent
applications in the U.S., Europe, Japan, China, and other
countries).